Botulinum Toxin Type A for Trigeminal Neuralgia: A Comprehensive Literature Review

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2024 Nov 26

PMID 39591255

Authors

Yan Tereshko

Simone Dal Bello

Christian Lettieri

Enrico Belgrado

Gian Luigi Gigli

Giovanni Merlino

Mariarosaria Valente

Affiliations

Soon will be listed here.

Abstract

Trigeminal neuralgia is a neuropathic pain syndrome responsive to botulinum toxin type A therapy. This review had the goal of analyzing the different studies published from 2002 to January 2024 to better define the techniques and the types of botulinum toxin type A used, the doses, the injection routes, and the different populations of trigeminal neuralgia patients treated. We considered only articles in which the therapy was administered to humans to treat trigeminal neuralgia. Case reports, case series, open-label, retrospective, and RCT studies were considered. The research was conducted on MEDLINE and the keywords included (trigeminal neuralgia) and (botulinum). Thirty-five articles were considered suitable for this review. Botulinum toxin type A was shown to be an effective therapy for TN pain in all the articles analyzed, albeit there is a lack of standardization in methods and outcomes. The techniques, the doses, and the injection approaches were very heterogeneous among the studies. Only two botulinum toxin type A formulations have been used in this setting: onabotulinumtoxinA and lanbotulinumtoxinA. There were 300 patients treated with onabotulinumtoxinA and 760 treated with lanbotulinumtoxinA overall (in 42 patients, the formulation was not specified). The distinction between etiological and clinical types of TN has been made by only a small portion of the studies. The main adverse event was transient facial asymmetry. Botulinum toxin type A is indeed a promising therapy that is clearly effective for trigeminal neuralgia. OnabotulinumtoxinA is the most common formulation used in Western countries; however, the meager sample of TN patients treated, and the lack of standardization are not sufficient for this therapy to be approved by the FDA or EMA. Indeed, more studies with standardized methods and larger samples are needed for this purpose.

References

Safarpour Y, Jabbari B . Botulinum Toxin Treatment of Movement Disorders. Curr Treat Options Neurol. 2018; 20(2):4. DOI: 10.1007/s11940-018-0488-3. View

Wu C, Lian Y, Zheng Y, Zhang H, Chen Y, Xie N . Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012; 32(6):443-50. DOI: 10.1177/0333102412441721. View

de Siqueira S, Nobrega J, Valle L, Teixeira M, de Siqueira J . Idiopathic trigeminal neuralgia: clinical aspects and dental procedures. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 98(3):311-5. DOI: 10.1016/S1079210404003191. View

Drinovac V, Bach-Rojecky L, Lackovic Z . Association of antinociceptive action of botulinum toxin type A with GABA-A receptor. J Neural Transm (Vienna). 2014; 121(6):665-9. DOI: 10.1007/s00702-013-1150-6. View

Mika J, Rojewska E, Makuch W, Korostynski M, Luvisetto S, Marinelli S . The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. Neuroscience. 2010; 175:358-66. DOI: 10.1016/j.neuroscience.2010.11.040. View

Xiao L, Cheng J, Zhuang Y, Qu W, Muir J, Liang H . Botulinum toxin type A reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain. Pain Med. 2013; 14(2):276-86. DOI: 10.1111/pme.12017. View

Dinan J, Smith A, Hawkins J . Trigeminal Neuralgia With Extraoral Trigger Zone Successfully Treated With Intraoral Injections of Botulinum Toxin: A Case Report. Clin Neuropharmacol. 2020; 43(5):162-163. DOI: 10.1097/WNF.0000000000000399. View

Li S, Lian Y, Chen Y, Zhang H, Ma Y, He C . Therapeutic effect of Botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up. J Headache Pain. 2014; 15:43. PMC: 4077143. DOI: 10.1186/1129-2377-15-43. View

Calejo M, Salgado P, Moreira B, Correia C, Barros J . Botulinum Toxin Type A Injections as an Effective Treatment of Refractory Multiple Sclerosis-Related Trigeminal Pain - A Case Report. Headache. 2019; 59(8):1379-1381. DOI: 10.1111/head.13609. View

10.

Marinkovic S, Gibo H, Todorovic V, Antic B, Kovacevic D, Milisavljevic M . Ultrastructure and immunohistochemistry of the trigeminal peripheral myelinated axons in patients with neuralgia. Clin Neurol Neurosurg. 2009; 111(10):795-800. DOI: 10.1016/j.clineuro.2009.07.020. View

11.

Hilton D, Love S, Gradidge T, Coakham H . Pathological findings associated with trigeminal neuralgia caused by vascular compression. Neurosurgery. 1994; 35(2):299-303; discussion 303. DOI: 10.1227/00006123-199408000-00017. View

12.

Wang L, Wang K, Chu X, Li T, Shen N, Fan C . Intra-articular injection of Botulinum toxin A reduces neurogenic inflammation in CFA-induced arthritic rat model. Toxicon. 2016; 126:70-78. DOI: 10.1016/j.toxicon.2016.11.009. View

13.

Wang S, Yue J, Xu Y, Xue L, Xiao W, Zhang C . [Preliminary report of botulinum toxin type A injection at trigger point for treatment of trigeminal neuralgia: experiences of 16 cases]. Shanghai Kou Qiang Yi Xue. 2014; 23(1):117-9. View

14.

Purkiss J, Welch M, Doward S, Foster K . Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2001; 59(11):1403-6. DOI: 10.1016/s0006-2952(00)00260-4. View

15.

Marinelli S, Vacca V, Ricordy R, Uggenti C, Tata A, Luvisetto S . The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One. 2012; 7(10):e47977. PMC: 3480491. DOI: 10.1371/journal.pone.0047977. View

16.

Marinelli S, Luvisetto S, Cobianchi S, Makuch W, Obara I, Mezzaroma E . Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience. 2010; 171(1):316-28. DOI: 10.1016/j.neuroscience.2010.08.067. View

17.

Finocchiaro A, Marinelli S, De Angelis F, Vacca V, Luvisetto S, Pavone F . Botulinum Toxin B Affects Neuropathic Pain but Not Functional Recovery after Peripheral Nerve Injury in a Mouse Model. Toxins (Basel). 2018; 10(3). PMC: 5869416. DOI: 10.3390/toxins10030128. View

18.

Kanpolat Y, Savas A, Bekar A, Berk C . Percutaneous controlled radiofrequency trigeminal rhizotomy for the treatment of idiopathic trigeminal neuralgia: 25-year experience with 1,600 patients. Neurosurgery. 2001; 48(3):524-32; discussion 532-4. DOI: 10.1097/00006123-200103000-00013. View

19.

Gupta A, Edwards S, Smith J, Snow J, Visvanathan R, Tucker G . A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain. Toxins (Basel). 2022; 14(1). PMC: 8780616. DOI: 10.3390/toxins14010036. View

20.

Lackovic Z, Filipovic B, Matak I, Helyes Z . Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches. Br J Pharmacol. 2015; 173(2):279-91. PMC: 5341233. DOI: 10.1111/bph.13366. View